Comerford E, Norcross L, Sasane M, Zheng Y, Gnanasakthy A. Patient-reported outcome (PRO) data in oncology NDAs approved by the FDA (2018–2021): a review of criticism and concerns in comments from regulators. Poster presented at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference; April 5, 2024. Orlando, FL. [abstract] J Natl Compr Canc Netw. 2024 Apr 5; 22(2.5). doi: 10.6004/jnccn.2023.7146
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.
DiBenedetti DB, Price MA, Andrews EB. Cognitive interviewing in risk minimization survey development: patient and healthcare professional surveys. Expert Rev Clin Pharmacol. 2013;6(4):369-73.